p53 Pathway Alterations Influence Survival and Treatment Response In Chronic Lymphocytic Leukemia
Hun Ju Lee, Miguel Gallardo, Xiaorui Zhang et al.
Key Points:
17p- mutation, containing p53 locus, major predictor poor outcome in CLL, but lack clarity how specific this mutation influence cancer progression
Mouse model of B-CLL (Eµ-TCL1) with fludarabine as cytotoxic treatment
Finding: fludarabine based therapies may have negative transformational impact on CLL progression if they have p53 mutations
Ibrutinib: superior treatment option compared to fludarabine when p53 mutations are present.
Implications:
- Combined fludaribine and Ibrutinib treatment can be option in this population.
View the original abstract on the ASH website.
